Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

By G. Demetri, A. van Oosterom, C. Garrett, M. Blackstein, M. Shah, J. Verweij, G. McArthur, I. Judson, M. Heinrich, J. Morgan and 7 more. The Lancet, 2006

2,477 citations recorded by the source corpus.

Subfields: Gastroenterology, Surgery

View Paper: https://www.semanticscholar.org/paper/0c0c1c281a38ef2833642a2e542ef85d7d4e6507

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

1. Christopher Corless
2. M. Heinrich
3. Heikki Joensuu

In Surgery

1. Christopher Corless
2. M. Heinrich

Citations in the corpus

• The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review) (2017, neutral): “Many of these kinases are now considered cancer biomarkers, such as EGFR for colon cancer, cKIT for GISTs, and human EGFR-related gene (Her2) for breast cancer (112).”
• Molecular basis for sunitinib efficacy and future clinical development (2007, background): “cgi?id=606764">gastrointestinal stromal tumours (GIST) that are refractory or intolerant to imatini”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “33 (0·23–0·47) 3 [134]”
• Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. (2011, background): “proved for use in imatinib-refractory GIST.(26,107) Although the aforementioned”
• Gastrointestinal stromal tumours: origin and molecular oncology (2011, background): “Sunitinib is US Food and Drug Administration (FDA)-approved for the treatment of patients with GISTs with progression on imatini”